HER2(Human Epidermal Growth Factor Receptor 2) -Positive Metastatic Breast Cancer in Russia
Clinical trial NCT05905939 · COMPLETED
Trial details
- NCT number
- NCT05905939
- Sponsor
- AstraZeneca
- Status
- COMPLETED
- Study type
- OBSERVATIONAL
- Start date
- 2023-05-31
- Primary completion
- 2024-03-29
- Enrollment
- 774
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.